|Bid||11.10 x 800|
|Ask||17.99 x 1100|
|Day's range||11.00 - 11.68|
|52-week range||11.00 - 51.19|
|Beta (5Y monthly)||0.82|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||43.38|
VANCOUVER, British Columbia & SEATTLE, January 19, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.
RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.
VANCOUVER, British Columbia & SEATTLE, January 15, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the "NYSE Rule"), an equity inducement award to Mr. Kenneth Galbraith, Zymeworks’ new Chair, President and Chief Executive Officer.